Related Experiment Videos
Lipokinetic studies with gemfibrozil (CI-719)
Proceedings of the Royal Society of Medicine
|January 1, 1976
Summary
Gemfibrozil effectively lowers high triglyceride levels in patients and animals. This study confirms its efficacy in treating endogenous hypertriglyceridaemia.
Area of Science:
- Pharmacology
- Biochemistry
- Clinical Medicine
Background:
- Endogenous hypertriglyceridaemia is a condition characterized by elevated plasma triglyceride levels.
- High triglyceride levels are associated with increased cardiovascular risk.
- Gemfibrozil (CI-719) has shown potential in managing hypertriglyceridaemia.
Purpose of the Study:
- To confirm the efficacy of Gemfibrozil in reducing plasma triglyceride levels.
- To validate previous findings in experimental animals and human patients.
Main Methods:
- Review of existing studies on Gemfibrozil's effect on triglyceride levels.
- Analysis of data from experimental animal models.
- Evaluation of clinical data from patients with endogenous hypertriglyceridaemia.
Main Results:
- Gemfibrozil demonstrated significant reduction in plasma triglyceride levels.
- The findings in experimental animals were consistent with those in human patients.
- The efficacy of Gemfibrozil in endogenous hypertriglyceridaemia was confirmed.
Conclusions:
- Gemfibrozil is an effective therapeutic agent for lowering plasma triglyceride levels.
- The study supports the use of Gemfibrozil in managing endogenous hypertriglyceridaemia.
- Further research may explore long-term effects and optimal dosing regimens.